Plans for a $1.68 billion cancer hospital in Boston — a joint venture among Boston-based Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center and Harvard Medical Faculty Physicians — are proceeding after the completion of a multi-agency, state and city regulatory process.
The 300-bed hospital, which was announced in September 2023 and received approval from the Boston Planning Department in October 2024, will be owned and managed by Dana-Farber and comprise 450,000 square feet and ten inpatient floors.
“The 18-month, rigorous review was conducted by several state and city agencies, including the Massachusetts Health Policy Commission, Massachusetts Department of Public Health and Boston Planning and Development Agency,” according to a July 7 news release.
Construction is expected to kick off in 2026, with an opening set for 2031. The hospital will create around 2,400 new jobs in clinical, imaging, laboratory services, nursing, pharmacy, radiation oncology and support services, the release said.
